Evidence supporting the use of: Cannabinoids
For the body system: Eyes

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Table of Contents

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Cannabinoids, particularly those derived from the Cannabis sativa plant such as delta-9-tetrahydrocannabinol (THC), have been scientifically studied for their effects on intraocular pressure (IOP), which is a key factor in glaucoma, a serious eye disease. Research dating back to the 1970s demonstrated that cannabinoids can lower IOP for several hours after administration, which prompted interest in their potential therapeutic role in glaucoma management. However, the effect is short-lived, and the side effect profile of cannabinoids, including psychoactive effects, cardiovascular changes, and potential for abuse, limits their clinical utility.

Despite their ability to temporarily reduce IOP, leading ophthalmic societies and the American Academy of Ophthalmology do not currently recommend cannabinoids as a first-line or adjunctive treatment for glaucoma, as safer and more effective medications are available. There is also insufficient evidence supporting cannabinoids for other eye conditions, such as macular degeneration or dry eye. Ongoing research continues to investigate the role of the endocannabinoid system in ocular health, but as of now, cannabinoid-based therapies for eye diseases remain experimental and are not widely endorsed by the medical community.

In summary, cannabinoids have a scientifically recognized, but limited, effect on eye physiology, specifically intraocular pressure, but concerns regarding safety, duration of action, and lack of superiority to existing treatments have prevented widespread clinical use for eye health.

More about Cannabinoids
More about Eyes

Products containing Cannabinoids

We currently have no products on Vitabase that contain this ingredient.